Lipoproteins, HDL

"Lipoproteins, HDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases.

Descriptor ID	D008075
MeSH Number(s)	D10.532.432 D12.776.521.479
Concept/Terms	Lipoproteins, HDL Lipoproteins, HDL HDL Lipoproteins Heavy Lipoproteins Lipoproteins, Heavy High-Density Lipoproteins High Density Lipoproteins Lipoproteins, High-Density alpha-Lipoproteins alpha Lipoproteins alpha-1 Lipoprotein alpha-1 Lipoprotein

Below are MeSH descriptors whose meaning is more general than "Lipoproteins, HDL".

Chemicals and Drugs [D]
Lipids [D10]
Lipoproteins [D10.532]
Lipoproteins, HDL [D10.532.432]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Lipoproteins [D12.776.521]
Lipoproteins, HDL [D12.776.521.479]

Below are MeSH descriptors whose meaning is related to "Lipoproteins, HDL".

Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, HDL".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lipoproteins, HDL" by people in this website by year, and whether "Lipoproteins, HDL" was a major or minor topic of these publications.

Bar chart showing 24 publications over 14 distinct years, with a maximum of 4 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	1	0	1
2001	2	0	2
2005	2	0	2
2006	0	1	1
2008	0	2	2
2010	1	1	2
2012	2	0	2
2013	1	1	2
2017	1	0	1
2018	1	1	2
2019	1	0	1
2020	1	0	1
2024	1	3	4

Below are the most recent publications written about "Lipoproteins, HDL" by people in Profiles.

Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. 2024 12 16; 45(47):5023-5038.

View in: PubMed
Gibson CM, Chi G, Duffy D, Bahit MC, White H, Korjian S, Alexander JH, Lincoff AM, Anschuetz G, Girgis IG, Nicolau JC, Lopes RD, Cornel JH, Bainey KR, Libby P, Sacks FM, Ridker PM, Goodman SG, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights?From the AEGIS-II Trial. J Am Coll Cardiol. 2024 Nov 26; 84(22):2185-2192.

View in: PubMed
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024 05 02; 390(17):1560-1571.

View in: PubMed
Povsic TJ, Korjian S, Bahit MC, Chi G, Duffy D, Alexander JH, Vinereanu D, Tricoci P, Mears SJ, Deckelbaum LI, Bonaca M, Ridker PM, Goodman SG, Cornel JH, Lewis BS, Parkhomenko A, Lopes RD, Aylward P, Lincoff AM, Heise M, Sacks F, Nicolau JC, Merkely B, Trebacz J, Libby P, Nicholls SJ, Pocock S, Bhatt DL, Kastelein J, Bode C, Mahaffey KW, Steg PG, Tendera M, Bainey KR, Harrington RA, Mehran R, Duerschmied D, Kingwell BA, Gibson CM. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors?of Acute MI. J Am Coll Cardiol. 2024 Jun 04; 83(22):2163-2174.

View in: PubMed
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Am Heart J. 2021 01; 231:121-127.

View in: PubMed
Wilkins JT, Gidding SS, Robinson JG. Can atherosclerosis be cured? Curr Opin Lipidol. 2019 12; 30(6):477-484.

View in: PubMed
Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2019 02; 208:81-90.

View in: PubMed
Ogunsile FJ, Bediako SM, Nelson J, Cichowitz C, Yu T, Patrick Carroll C, Stewart K, Naik R, Haywood C, Lanzkron S. Metabolic syndrome among adults living with sickle cell disease. Blood Cells Mol Dis. 2019 02; 74:25-29.

View in: PubMed
Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman AM, Rader DJ. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci. 2017 Nov; 10(6):455-469.

View in: PubMed
Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement